Skip to main content
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1995 Apr;71(2):92–93. doi: 10.1136/sti.71.2.92

Quercetin and kaempherol: an argument against the use of podophyllin?

C S Petersen 1, K Weismann 1
PMCID: PMC1195461  PMID: 7744421

Abstract

INTRODUCTION--Topical application of podophyllin is a routine procedure in patients with ano-genital warts. Podophyllin is a crude plant extract and is therefore not a well-defined product. It may contain variable amounts of the active lignan podophyllotoxin and the majority of the dry weight of podophyllin is made up of substances never identified. OBJECTIVE--The purpose of the study was to estimate in podophyllin 20% the amounts of two mutagenic substances, quercetin and kaempherol. METHODS--Using high-pressure liquid chromatography the amounts of quercetin and kaempherol were determined in 3 batches of podophyllin 20%. RESULTS--Quercetin and kaempherol constitutes 2.5-3.8% and 6.0-6.4% of podophyllin dry substance, respectively. Podophyllotoxin constitutes in comparison 12.7-13.8% of podophyllin dry substance. CONCLUSION--As approximately 10% of the amount of dry substance in podophyllin 20% is composed of two mutagenic flavonoids, quercetin and kaempherol, efforts should be focused on the production of a well-defined purified podophyllotoxin preparation that may replace podophyllin for clinic use in patients with genital warts. Self-medication with purified podophyllotoxin 0.5% may be considered as first-line treatment in well-instructed patients with external genital warts.

Full text

PDF
92

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERENBLUM I. The effect of podophyllotoxin on the skin of the mouse, with reference to carcinogenic, cocarcinogenic, and anticarcinogenic action. J Natl Cancer Inst. 1951 Feb;11(4):839–841. [PubMed] [Google Scholar]
  2. Beutner K. R., Conant M. A., Friedman-Kien A. E., Illeman M., Artman N. N., Thisted R. A., King D. H. Patient-applied podofilox for treatment of genital warts. Lancet. 1989 Apr 15;1(8642):831–834. doi: 10.1016/s0140-6736(89)92282-4. [DOI] [PubMed] [Google Scholar]
  3. Brown J. P., Dietrich P. S. Mutagenicity of plant flavonols in the Salmonella/mammalian microsome test: activation of flavonol glycosides by mixed glycosidases from rat cecal bacteria and other sources. Mutat Res. 1979 Mar;66(3):223–240. doi: 10.1016/0165-1218(79)90083-1. [DOI] [PubMed] [Google Scholar]
  4. Campo M. S. Papillomas and cancer in cattle. Cancer Surv. 1987;6(1):39–54. [PubMed] [Google Scholar]
  5. Greenberg M. D., Rutledge L. H., Reid R., Berman N. R., Precop S. L., Elswick R. K., Jr A double-blind, randomized trial of 0.5% podofilox and placebo for the treatment of genital warts in women. Obstet Gynecol. 1991 May;77(5):735–739. [PubMed] [Google Scholar]
  6. KELLY M., HARTWELL J. L. The biological effects and the chemical composition of podophyllin: a review. J Natl Cancer Inst. 1954 Feb;14(4):967–1010. [PubMed] [Google Scholar]
  7. Takenaka S., Sera N., Tokiwa H., Hirohata I., Hirohata T. Identification of mutagens in Japanese pickles. Mutat Res. 1989 May;223(1):35–40. doi: 10.1016/0165-1218(89)90060-8. [DOI] [PubMed] [Google Scholar]
  8. Wade T. R., Ackerman A. B. The effects of resin of podophyllin on condyloma acuminatum. Am J Dermatopathol. 1984 Apr;6(2):109–122. doi: 10.1097/00000372-198404000-00002. [DOI] [PubMed] [Google Scholar]
  9. von Krogh G. Topical treatment of penile condylomata acuminata with podophyllin, podophyllotoxin and colchicine. A comparative study. Acta Derm Venereol. 1978;58(2):163–168. [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES